Longeveron Inc. (NASDAQ:LGVN) Sees Significant Decrease in Short Interest

Longeveron Inc. (NASDAQ:LGVN) saw a significant decline in short interest in December. As of December 31st, there was short interest totaling 979,704 shares, a decline of 26.6% from the December 15th total of 1,334,145 shares. Based on an average daily trading volume, of 372,571 shares, the short-interest ratio is currently 2.6 days. Currently, 5.2% of the shares of the stock are short sold. Currently, 5.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 372,571 shares, the short-interest ratio is currently 2.6 days.

Longeveron Trading Down 2.1%

Longeveron stock traded down $0.01 during trading hours on Friday, reaching $0.55. 75,911 shares of the stock were exchanged, compared to its average volume of 229,422. Longeveron has a twelve month low of $0.49 and a twelve month high of $1.92. The company has a market cap of $11.77 million, a P/E ratio of -0.52 and a beta of 0.21. The stock has a 50 day moving average of $0.60 and a two-hundred day moving average of $0.87.

Longeveron (NASDAQ:LGVN) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.13). The firm had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.29 million. Longeveron had a negative return on equity of 138.44% and a negative net margin of 1,485.25%. On average, analysts expect that Longeveron will post -3.69 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Longeveron in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $6.50.

Hedge Funds Weigh In On Longeveron

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd purchased a new position in shares of Longeveron Inc. (NASDAQ:LGVN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron as of its most recent filing with the SEC. Institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.